RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LAGEVRIO™ (molnupiravir) did not demonstrate a statistically significant ...

A preliminary analysis of the University of Oxford’s open label, prospective real-world evidence study, PANORAMIC, conducted in the UK in highly-vaccinated adults mostly <65 years of age, showed no ...

The U.S. government will stop distributing free doses of Merck & Co's COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead.

A new study published Monday links COVID-19 antiviral created by Merck with new mutations of the virus that have been sequenced around the world. Molnupiravir, known commercially as Lagevrio, is one ...

A new study said Merck's widely used antiviral Covid pill can cause mutations in the virus that occasionally spread to other people. But there is no evidence that molnupiravir, sold under the brand ...

LONDON, Dec 22 (Reuters) - Merck & Co Inc's (MRK.N), opens new tab COVID antiviral molnupiravir speeds up recovery but does not reduce the hospitalisation or death rate in higher-risk vaccinated ...

NEW YORK, Sept 28 (Reuters) - Drugmaker Merck & Co (MRK.N), opens new tab said on Wednesday that it agreed to allow China's Sinopharm (1099.HK), opens new tab to distribute and import its COVID-19 ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. (The Hill) – A new study published Monday ...